2025 revenue consensus $438.17M. Narrows 2025 adjusted EBITDA view to $88M-$91M vs. $86M-$91M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion announces treatment of first patient in ARTIZEN pivotal trial
- AORT Upcoming Earnings Report: What to Expect?
- Artivion Inc. Advances Aortic Treatment with New Clinical Study
- Artivion announces data from AMDS PERSEVERE and PROTECT trials
- Artivion price target raised to $47 from $42 at Citizens JMP